CompletedPHASE1, PHASE2NCT01761292

A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMD

Studying Duchenne muscular dystrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Italfarmaco
Principal Investigator
Enrico Bertini, MD
Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Intervention
Givinostat(drug)
Enrollment
20 enrolled
Eligibility
7-11 years · MALE
Timeline
20132017

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01761292 on ClinicalTrials.gov

Other trials for Duchenne muscular dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Duchenne muscular dystrophy

← Back to all trials